Patents by Inventor Masayuki Tsuchiya
Masayuki Tsuchiya has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20120156724Abstract: The present invention relates to humanized antibodies binding to CD47; diabodies binding to human CD47, characterized in that a disulfide bond exists between diabody-forming fragments; genes encoding any one of said antibodies; vectors containing said genes; host cells containing said vectors; processes for preparing antibodies comprising the step of culturing said host cells; and therapeutic agents for hematological disorders comprising said antibodies.Type: ApplicationFiled: December 19, 2011Publication date: June 21, 2012Inventors: Yasufumi Kikuchi, Shinsuke Uno, Yasuko Kinoshita, Shigeyuki Iijima, Naoshi Fukushima, Masayuki Tsuchiya
-
Patent number: 8158385Abstract: To identify antigens of the 2D7 antibody, the present inventors cloned the 2D7 antigen. The results suggested that the 2D7 antigen is an HLA class I molecule. Based on this finding, the present inventors examined whether the 2D7 antibody has cell death-inducing activity. Nuclei fragmentation was observed when the 2D7 antibody was cross-linked with another antibody, indicating that cell-death was induced. Further, diabodies of the 2D7 antibody were found to have very strong cell death-inducing activities, even without the addition of another antibody. These results indicate that minibodies of an HLA-recognizing antibody can be used as cell death-inducing agents.Type: GrantFiled: October 10, 2003Date of Patent: April 17, 2012Assignees: Chugai Seiyaku Kabushiki KaishaInventors: Shuji Ozaki, Masahiro Abe, Masayuki Tsuchiya, Naoki Kimura, Shigeto Kawai
-
Patent number: 8105799Abstract: Revealed are that the actions of inflammatory cytokine and the production of inflammatory cytokines such as IL-1 and TNF induced by an inflammatory stimulus as well as the production of other inflammatory cytokines such as IL-6 induced by the former class of inflammatory cytokines are all suppressed by inhibiting the signal transduction through TAK1.Type: GrantFiled: February 6, 2008Date of Patent: January 31, 2012Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Masayuki Tsuchiya, Toshihiko Ohtomo, Yasuhiro Sugamata, Kunihiro Matsumoto
-
Patent number: 8101719Abstract: The present invention relates to humanized antibodies binding to CD47; diabodies binding to human CD47, characterized in that a disulfide bond exists between diabody-forming fragments; genes encoding any one of said antibodies; vectors containing said genes; host cells containing said vectors; processes for preparing antibodies comprising the step of culturing said host cells; and therapeutic agents for hematological disorders comprising said antibodies.Type: GrantFiled: November 11, 2004Date of Patent: January 24, 2012Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Yasufumi Kikuchi, Shinsuke Uno, Yasuka Kinoshita, Shigeyuki Iijima, Naoshi Fukushima, Masayuki Tsuchiya
-
Publication number: 20120015436Abstract: The invention relates to a modified antibody which contains two or more H chain V regions and two or more L chain V regions of monoclonal antibody and can transduce a signal into cells by crosslinking TPO receptor to thereby exert TPO agonist action. The modified antibody can be used as a TPO signal transduction agonist and, therefore, useful as a remedy for various diseases such as platelet-reduction-related blood diseases, thrombopenia following chemotherapy for cancer or leukemia, etc.Type: ApplicationFiled: September 6, 2011Publication date: January 19, 2012Inventors: Masayuki Tsuchiya, Toshihiko Ohtomo, Naohiro Yabuta, Hiroyuki Tsunoda, Tetsuro Orita
-
Publication number: 20120015402Abstract: An objective of the present invention is to facilitate the acquisition of antibody-producing cells that are infiltrating virus-infected cells, cancer cells, abnormal cells forming a benign hyperplasia, and the like, and to improve the efficiency of the production of antibodies as well as nucleic acids encoding them from the antibody-producing cells. The present inventors discovered that, when cancer tissues comprising infiltrating lymphocytes are transplanted into highly immunodeficient animals that do not have T cells, B cells, and NK cells and further exhibit a low IFN production ability, the differentiation and proliferation of infiltrating lymphocytes are unexpectedly promoted, and the number of plasma cells that produce antibodies recognizing cancer tissues increases dramatically, plasma cells can be separated easily, and antibodies or nucleic acids encoding them can be easily prepared from the plasma cells.Type: ApplicationFiled: July 21, 2011Publication date: January 19, 2012Applicants: CHUGAI SEIYAKU KABUSHIKI KAISHA, CIEA INTERNATIONAL INC., PHARMALOGICALS RESEARCH PTE. LTD.Inventors: Masayuki Tsuchiya, Masami Suzuki, Kenji Yoshida, Etsuko Fujii, Miho Watanabe, Koichi Matsubara, Yu Jau Chen, Juliana Sim
-
Patent number: 8034903Abstract: The invention relates to a modified antibody which contains two or more H chain V regions and two or more L chain V regions of monoclonal antibody and can transduce a signal into cells by crosslinking TPO receptor to thereby exert TPO agonist action. The modified antibody can be used as a TPO signal transduction agonist and, therefore, useful as a remedy for various diseases such as platelet-reduction-related blood diseases, thrombopenia following chemotherapy for cancer or leukemia, etc.Type: GrantFiled: October 22, 2001Date of Patent: October 11, 2011Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Masayuki Tsuchiya, Toshihiko Ohtomo, Naohiro Yabuta, Hiroyuki Tsunoda, Tetsuro Orita
-
Patent number: 8008073Abstract: Anti-human Mpl antibodies were isolated and purified. Anti-human Mpl diabodies and anti-human Mpl sc(Fv)2 were prepared using genetic engineering techniques and anti-human Mpl sc(Fv)2 was also humanized. The diabodies and sc(Fv)2 were assayed for TPO-like agonistic activity, and were found to have activities higher than those of anti-human Mpl antibodies, or activities equivalent to or higher than those of naturally-occurring human TPO ligand.Type: GrantFiled: September 2, 2010Date of Patent: August 30, 2011Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Hiroyuki Tsunoda, Kiyotaka Nakano, Tetsuro Orita, Masayuki Tsuchiya, Yuichi Hirata
-
Patent number: 8008076Abstract: An objective of the present invention is to facilitate the acquisition of antibody-producing cells that are infiltrating virus-infected cells, cancer cells, abnormal cells forming a benign hyperplasia, and the like, and to improve the efficiency of the production of antibodies as well as nucleic acids encoding them from the antibody-producing cells. The present inventors discovered that, when cancer tissues comprising infiltrating lymphocytes are transplanted into highly immunodeficient animals that do not have T cells, B cells, and NK cells and further exhibit a low IFN production ability, the differentiation and proliferation of infiltrating lymphocytes are unexpectedly promoted, and the number of plasma cells that produce antibodies recognizing cancer tissues increases dramatically, plasma cells can be separated easily, and antibodies or nucleic acids encoding them can be easily prepared from the plasma cells.Type: GrantFiled: April 27, 2005Date of Patent: August 30, 2011Assignees: Chugai Seiyaku Kabushiki Kaisha, Pharmalogicals Research Pte. Ltd., CIEA International Inc.Inventors: Masayuki Tsuchiya, Masami Suzuki, Kenji Yoshida, Etsuko Fujii, Miho Watanabe, Koichi Matsubara, Yu Jau Chen, Juliana Sim
-
Patent number: 7993642Abstract: Anti-human Mpl antibodies were isolated and purified. Anti-human Mpl diabodies and anti-human Mpl sc(Fv)2 were prepared using genetic engineering techniques and anti-human Mpl sc(Fv)2 was also humanized. The diabodies and sc(Fv)2 were assayed for TPO-like agonistic activity, and were found to have activities higher than those of anti-human Mpl antibodies, or activities equivalent to or higher than those of naturally-occurring human TPO ligand.Type: GrantFiled: December 10, 2004Date of Patent: August 9, 2011Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Hiroyuki Tsunoda, Kiyotaka Nakano, Tetsuro Orita, Masayuki Tsuchiya, Yuichi Hirata
-
Publication number: 20110070614Abstract: The present invention provides a gene encoding a fucose transporter, a fucose transporter polypeptide, a method for screening for a compound that binds to a fucose transporter or a compound that inhibits fucose transport activity, a cell having inhibited fucose transporter functions, and a cell wherein the expression of the fucose transporter is inhibited.Type: ApplicationFiled: November 23, 2010Publication date: March 24, 2011Inventors: MASAYUKI TSUCHIYA, SHIGEYUKI IIJIMA, IZUMI SUGO, YASUO SEKIMORI, KENJU UENO, KIYOSHI HABU
-
Publication number: 20110059488Abstract: Anti-human Mpl antibodies were isolated and purified, and then anti-human Mpl diabodies and anti-human Mpl sc(Fv)2 were purified using genetic engineering techniques. Furthermore, the present inventors succeeded in humanizing anti-human Mpl sc(Fv)2. The diabodies and sc(Fv)2 were assayed for TPO-like agonistic activity, and were found to have activities higher than those of anti-human Mpl antibodies, or activities equivalent to or higher than those of naturally-occurring human TPO ligand.Type: ApplicationFiled: September 2, 2010Publication date: March 10, 2011Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Hiroyuki Tsunoda, Kiyotaka Nakano, Tetsuro Orita, Masayuki Tsuchiya, Yuichi Hirata
-
Patent number: 7892543Abstract: The invention provides a reshaped human anti-HM 1.24 antibody having: (A) an L chain having (1) the C region of a human L chain, and (2) the V region of an L chain having the FR of a human L chain and the CDR of the L chain of a mouse anti-HM 1.24 monoclonal antibody; and (B) an H chain having (1) the C region of a human H chain, and (2) the V region of an H chain having the FR of a human H chain and the CDR of the H chain of a mouse anti-HM 1.24 monoclonal antibody. This reshaped human antibody is derived from human antibody and the CDR has a low antigenicity, and the reshaped human antibody of the present invention has a low antigenicity and can be used for medical treatment.Type: GrantFiled: August 13, 2002Date of Patent: February 22, 2011Assignee: Chugai Seiyako Kabushiki KaishaInventors: Koichiro Ono, Toshihiko Ohtomo, Masayuki Tsuchiya, Yasushi Yoshimura, Yasuo Koishihara, Masaaki Kosaka
-
Publication number: 20110002922Abstract: Provided is a cell growth inhibitor that can be used for treating diseases based on abnormal cell proliferation, and in particular cancer. The cell growth inhibitor contains an anti-glypican 3 antibody as an active ingredient.Type: ApplicationFiled: April 26, 2010Publication date: January 6, 2011Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Hiroyuki Aburatani, Tetsuo Nakamura, Masayuki Tsuchiya
-
Patent number: 7863042Abstract: The present invention provides a gene encoding a fucose transporter, a fucose transporter polypeptide, a method for screening for a compound that binds to a fucose transporter or a compound that inhibits fucose transport activity, a cell having inhibited fucose transporter functions, and a cell wherein the expression of the fucose transporter is inhibited.Type: GrantFiled: June 18, 2004Date of Patent: January 4, 2011Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Masayuki Tsuchiya, Shigeyuki Iijima, Izumi Sugo, Yasuo Sekimori, Kenju Ueno, Kiyoshi Habu
-
Publication number: 20100172899Abstract: IgM can be obtained in the form of a pentamer by placing the genes encoding the H, L, and J chains on the same vector to transform appropriate host cells. The gene encoding the J chain may be introduced by co-transfection. When no J chain is expressed, the IgM is produced as a hexamer. The transformants obtained according to the present invention achieve a high yield of IgM. The present invention also provides methods which enable separation and quantification of polymeric IgM.Type: ApplicationFiled: March 18, 2010Publication date: July 8, 2010Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Reiko Irie, Hiroyuki Tsunoda, Tomoyuki Igawa, Yasuo Sekimori, Masayuki Tsuchiya
-
Patent number: 7744880Abstract: Provided is a cell growth inhibitor that can be used for treating diseases based on abnormal cell proliferation, and in particular cancer. The cell growth inhibitor contains an anti-glypican 3 antibody as an active ingredient.Type: GrantFiled: February 5, 2007Date of Patent: June 29, 2010Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Hiroyuki Aburatani, Tetsuo Nakamura, Masayuki Tsuchiya
-
Patent number: 7709615Abstract: IgM can be obtained in the form of a pentamer by placing the genes encoding the H, L, and J chains on the same vector to transform appropriate host cells. The gene encoding the J chain may be introduced by co-transfection. When no J chain is expressed, the IgM is produced as a hexamer. The transformants obtained according to the present invention achieve a high yield of IgM. The present invention also provides methods which enable separation and quantification of polymeric IgM.Type: GrantFiled: July 15, 2004Date of Patent: May 4, 2010Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Reiko Irie, Hiroyuki Tsunoda, Tomoyuki Igawa, Yasuo Sekimori, Masayuki Tsuchiya
-
Patent number: 7696325Abstract: This invention relates to reconstructed polypeptides which have properties of inducing apoptosis of nucleated blood cells having Integrin Associated Protein (IAP) and causing no hemagglutination. The reconstructed polypeptides comprise two or more H chain V regions and two or more L chain V regions of a monoclonal antibody which induces apoptosis of nucleated blood cells having IAP. The reconstructed polypeptides are useful as a therapeutic agent for blood dyscrasia such as leukemia.Type: GrantFiled: March 12, 2001Date of Patent: April 13, 2010Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Naoshi Fukushima, Masayuki Tsuchiya, Masayoshi Oh-Eda, Shinsuke Uno, Yasufumi Kikuchi
-
Patent number: 7691588Abstract: The present inventors used antibody engineering techniques to prepare functional antibodies that correspond to individual mutations in causative genes of diseases, and discovered that such antibodies enable the treatment of the diseases. Specifically, the inventors succeeded in preparing ligands, particularly minibodies, which have agonistic activity to receptors that have almost completely lost responsiveness to their natural ligands because of gene mutations (for example, a thrombopoietin (TPO) receptor whose reactivity to TPO has been markedly impaired), and which can transduce signals by interacting with these mutant receptors at levels comparable to normal.Type: GrantFiled: March 12, 2004Date of Patent: April 6, 2010Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Masayuki Tsuchiya, Yuichi Hirata